Latest news:

BioStock article: New data strengthens Follicum’s diabetes project

BioStock published an article on 30 March 2021 about Follicum, which can be read in full below. Follicum, a company that develops tissue repair peptides, has advanced further in its preclinical work with developing a drug candidate for the treatment of diabetes. Through extensive and advanced experimental work, the company believes that the peptides bind […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Presentation BioStock Life Science Summit 2020, November 18

Hair growth

Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more